BRIEF-Genmab Says Johnson & Johnson Will Not Exercise Option For Hexabody-Cd38 License

Reuters
11 Mar
BRIEF-Genmab Says Johnson & Johnson Will Not Exercise Option For Hexabody-Cd38 License

March 10 (Reuters) - Genmab A/S GMAB.CO:

  • GENMAB ANNOUNCES JOHNSON & JOHNSON DECISION REGARDING HEXABODY®-CD38

  • GENMAB A/S - JOHNSON & JOHNSON WILL NOT EXERCISE OPTION FOR HEXABODY-CD38 LICENSE

  • GENMAB A/S - WILL NOT PURSUE FURTHER CLINICAL DEVELOPMENT OF HEXABODY-CD38

  • GENMAB A/S - NEWS DOES NOT IMPACT GENMAB'S 2025 FINANCIAL GUIDANCE

Source text: ID:nGNX9tBt34

Further company coverage: GMAB.CO

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10